
Cark of the House of Representatives Logislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



10 FEB 15 AM 9: 21

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

I. Registrant Name Alpine Group, Inc.			
•	Suite 201 DC 20003		
3. Principal Place of Business (if different from line 2)			
City State/Zip (or Constry)			
•	if (aptional) 5. Senate ID #  opec@stpinegroup.com		
7. Client Same 🗍 Self  DuPont Pharmaceuticals Company	6. House ID# 31749006		
INCOME OR EXPENSES - Complete Either			
12. Lobbying Firms	13. Organizations		
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:		
Less than \$10,000 📑	Less than \$10,000 🖂		
\$10,000 or more 🔀 >> \$ \$40,000.00   	\$10,000 or more		
Provide a good faith estimate, rounded to the nearest	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.		
\$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity	☐ Method A. Reporting amounts using LDA definitions only		
for lobbying activities on behalf of the client).	Method B. Reporting amounts under section 6033(b)(8) of the internal Revenue Code		
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code		
"			
ignature	Date 02/05/2000		

Reg	istrant Name:	Alpine Group, Inc.	
Clie	or Name:	DuPont Phormaceuticals Company	
enga	aged in lobbyin	FIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant ag on behalf of the client during the reporting period. Using a separate page for each code, provide uested. Attach additional page(s) as needed.	
15.	General issue	area code HCR (one per page)	
16.	Specific Lobb	bying issues A issues relating to substitution of NTI drugs and patient notification of switching of NTI drugs.	
	Ochelai i Da	s issues retaining to substitution of it is an ago and passers normalion of switching of term alags.	
17.	House(s) of C House of Rep Senate	Congress and Federal agencies contacted C Check if None presentatives	
18.	Name of each	a individual who acted as a lobbyist in this issue area	
	Name	Covered Official Position (if applicable)	New
	White, Richa	!	No
	· · · · · · · · · · · · · · · · · · ·		
			{
19.	Interest of eac	ch foreign entity in the specific issues listed on line 16 above   Check if None	
Sign	eature	Date 92/05/2000	
Prin	ted Name and T	Title Monica Skopec - Associate Pag	ge 2 of 3
	:		

Registrant Name:	Alpine Group, Inc.		
Dient Name:	DaPont Pharmaceuticals Company		
ngaged in lobbyi	FIVITY. Select as many codes as necessary og on behalf of the client during the reporti- uested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ing period. Using a separate page for each code, provide i.	
<ol> <li>General issu</li> <li>Specific Lob</li> </ol>	e area code TRD (one per page)		
:		·	
	Congress and Federal agencies contacted presentatives	☐ Check if None	
<ol> <li>Name of eac Name</li> </ol>	n individual who acted as a lobhyist in this	<b>:</b>	New
		issue area Covered Official Position (if applicable)	New No
Name		<b>:</b>	-
Name White, Rich		Covered Official Position (if applicable)	-